Company
Headquarters: Boston, MA, United States
Employees: 67
CEO: Dr. Mark Manfredi Ph.D.
$64.2 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $9.2 M |
| EBITDA | $-74,397,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -3324.43% |
| Quarterly Revenue Growth | -87.90% |
Ikena Oncology, Inc. has the following listings and related stock indices.
Stock: NASDAQ: IKNA